Some of our members



As by 2016 we do have now different kind of members. Our membership is based on organizations within the public agencies area, but also from academic area. In addition, personal members can request membership


Our global membership


AETSA, Fundacion Pública Andaluza Progreso Y Salud (ES)




AETSA


AGENAS, Agenzia nazionale per i servizi sanitari regionali (IT)




AGENAS


avalia-t, Agencia Gallega para la Gestión del Conocimiento en Salud, ACIS Unidad de Asesoramiento Científico-técnico (ES)




avalia-t


CONITEC, National Committee for Health Technology Incorporation Esplanada dos Ministérios (BR)




Conitec


HTRG, COAG Health Council

Health Technology Reference Group (AU)




HTRG


IHSP, Italian Horizon Scanning Project

UOC Assitenza Farmaceutica Territoriale (IT)




IHSP


ISCIII, Instituto de Salud Carlos III (ES)




ICSIII


MaHTAs, Ministry of Health Malaysia, Health Technology Assessment Section (MY)




MaHTAs


NECA, Department of Horizon Scanning for Innovative Global Health Technology, National Evidence-based Healthcare Collaborating Agency (KR)




NECA


NIHR IO, National Institute of Health Research

Innovation Observatory (UK)




NIHR IO


OSTEBA, Basque Office for Health Technology Assessment (ES)




OSTEBA


SFOPH, Swiss Federal Office of Public Health, Health and Accident Insurance (CH)




SFOPH


ACE, Agency for care effectiveness (SG)




ACE


CDE, Center for Drug Evaluation (TW)




CDE


AIS, Agence de l’innovation en santé (FR)




AIS


INCa, Institut national du cancer (FR)




INCa




Some of our organizational members






1

Stevens A, Milne R, Lilford R, Gabbay J. How do new technologies get into practice? Keeping pace with

new technologies: systems needed to identify and evaluate them. BMJ 1999 (319): 1291-4 2 http://www.phrma.org/medicines_in_development (last access December 2007) 3

Bertele’ V, Banzi R, Capasso F, Tafuri G, Trotta F, Apolone G, Garattini S. Haematological anticancer drugs

in Europe: any added value at the time of approval? Eur J Clin Pharmacol. 2007;63(7):713-9.

4

Garattini S, Bertelè V. How can we regulate medicines better? BMJ. 2007; 335(7624):803-5.

5

Joppi R, Bertele V, Garattini S. Orphan drug development is progressing too slowly. Br J Clin Pharmacol.

2006 Mar;61(3):355-60

6 Banta HD. Introduction to the EUR-ASSESS report. Int J Technol Assess Health Care 1997 (13): 133-143

7 Hailey D, Topfer LA, Willis F. Providing information on emerging health technologies to provincial

decision makers: a pilot project Health Policy 2001 Oct; 58 (1): 15-26

8 Simpson S, Vonderling H, Eskildsen D, Simpson S. Use of the Internet in Scanning the Horizon for New

and Emerging Health Technologies: A Survey of Agencies Involved in Horizon Scanning. J Med Internet Res

2003; 5 (1): 1-10

9 Douw K, Vondeling H. Selection of new health technologies for assessment aimed at informing decision

making: A survey among horizon scanning systems. Int J Technol Assess Health Care 2006; 22 (2): 177-183

10 Murphy K, Packer C, Stevens A, Simpson S. Effective early warning systems for new and emerging

technologies: Developing an evaluation framework and an assessment of current systems. Int J Technol

Assess Health Care 2007 (3): 324-330

11 Murphy K, Packer C, Stevens A, Simpson S. Effective early warning systems for new and emerging

technologies: Developing an evaluation framework and an assessment of current systems. Int J Technol

Assess Health Care 2007 (3): 324-330

12 Martelli F, La Torre G, Di Ghionno E, Staniscia T, Neroni T, Cicchetti A, Von Bremen K, Ricciardi W.

Health technology assessment agencies: An international overview of organizational aspects. Int J Technol

Assess Health Care 2007; 23 (4): 414-424

13 Battista RN, Expanding the scientific basis of health technology assessment: a research agenda for the next

  • decade. Int J Technol Assess Health Care. 2006; 22(3):275-80